Pharmacological treatment in Parkinson's disease: Effects on gait

Katrijn Smulders, Marian Dale, Patricia Carlson-Kuhta, John Nutt, Fay Horak

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Gait impairments are a hallmark of Parkinson's disease (PD), both as early symptom and an important cause of disability later in the disease course. Although levodopa has been shown to improve gait speed and step length, the effect of dopamine replacement therapy on other aspects of gait is less well understood. In fact, falls are not reduced and some aspects of postural instability during gait are unresponsive to dopaminergic treatment. Moreover, many medications other than dopaminergic agents, can benefit or impair gait in people with PD. We review the effects of pharmacological interventions used in PD on gait, discriminating, whenever possible, among effects on four components of everyday mobility: straight walking, gait initiation, turning, gait adaptability. Additionally, we summarize the effects on freezing of gait. There is substantial evidence for improvement of spatial characteristics of simple, straight-ahead gait with levodopa and levodopa-enhancing drugs. Recent work suggests that drugs aiming to enhance the acetylcholine system might improve gait stability measures. There is a lack of well-designed studies to evaluate effects on more complex, but highly relevant walking abilities such as turning and making flexible adjustments to gait. Finally, paucity in the literature exists on detrimental effects of drugs used in PD that are known to worsen gait and postural stability in the elderly population.

Original languageEnglish (US)
Pages (from-to)3-13
Number of pages11
JournalParkinsonism and Related Disorders
Volume31
DOIs
StatePublished - Oct 1 2016

Fingerprint

Gait
Parkinson Disease
Pharmacology
Levodopa
Therapeutics
Walking
Pharmaceutical Preparations
Dopamine Agents
Freezing
Acetylcholine
Dopamine

Keywords

  • Acetylcholine
  • Dopamine
  • Falls
  • Gait
  • Turning

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology

Cite this

Pharmacological treatment in Parkinson's disease : Effects on gait. / Smulders, Katrijn; Dale, Marian; Carlson-Kuhta, Patricia; Nutt, John; Horak, Fay.

In: Parkinsonism and Related Disorders, Vol. 31, 01.10.2016, p. 3-13.

Research output: Contribution to journalReview article

Smulders, Katrijn ; Dale, Marian ; Carlson-Kuhta, Patricia ; Nutt, John ; Horak, Fay. / Pharmacological treatment in Parkinson's disease : Effects on gait. In: Parkinsonism and Related Disorders. 2016 ; Vol. 31. pp. 3-13.
@article{92f99e34dcb1404885e0915d14b4ac61,
title = "Pharmacological treatment in Parkinson's disease: Effects on gait",
abstract = "Gait impairments are a hallmark of Parkinson's disease (PD), both as early symptom and an important cause of disability later in the disease course. Although levodopa has been shown to improve gait speed and step length, the effect of dopamine replacement therapy on other aspects of gait is less well understood. In fact, falls are not reduced and some aspects of postural instability during gait are unresponsive to dopaminergic treatment. Moreover, many medications other than dopaminergic agents, can benefit or impair gait in people with PD. We review the effects of pharmacological interventions used in PD on gait, discriminating, whenever possible, among effects on four components of everyday mobility: straight walking, gait initiation, turning, gait adaptability. Additionally, we summarize the effects on freezing of gait. There is substantial evidence for improvement of spatial characteristics of simple, straight-ahead gait with levodopa and levodopa-enhancing drugs. Recent work suggests that drugs aiming to enhance the acetylcholine system might improve gait stability measures. There is a lack of well-designed studies to evaluate effects on more complex, but highly relevant walking abilities such as turning and making flexible adjustments to gait. Finally, paucity in the literature exists on detrimental effects of drugs used in PD that are known to worsen gait and postural stability in the elderly population.",
keywords = "Acetylcholine, Dopamine, Falls, Gait, Turning",
author = "Katrijn Smulders and Marian Dale and Patricia Carlson-Kuhta and John Nutt and Fay Horak",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.parkreldis.2016.07.006",
language = "English (US)",
volume = "31",
pages = "3--13",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Pharmacological treatment in Parkinson's disease

T2 - Effects on gait

AU - Smulders, Katrijn

AU - Dale, Marian

AU - Carlson-Kuhta, Patricia

AU - Nutt, John

AU - Horak, Fay

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Gait impairments are a hallmark of Parkinson's disease (PD), both as early symptom and an important cause of disability later in the disease course. Although levodopa has been shown to improve gait speed and step length, the effect of dopamine replacement therapy on other aspects of gait is less well understood. In fact, falls are not reduced and some aspects of postural instability during gait are unresponsive to dopaminergic treatment. Moreover, many medications other than dopaminergic agents, can benefit or impair gait in people with PD. We review the effects of pharmacological interventions used in PD on gait, discriminating, whenever possible, among effects on four components of everyday mobility: straight walking, gait initiation, turning, gait adaptability. Additionally, we summarize the effects on freezing of gait. There is substantial evidence for improvement of spatial characteristics of simple, straight-ahead gait with levodopa and levodopa-enhancing drugs. Recent work suggests that drugs aiming to enhance the acetylcholine system might improve gait stability measures. There is a lack of well-designed studies to evaluate effects on more complex, but highly relevant walking abilities such as turning and making flexible adjustments to gait. Finally, paucity in the literature exists on detrimental effects of drugs used in PD that are known to worsen gait and postural stability in the elderly population.

AB - Gait impairments are a hallmark of Parkinson's disease (PD), both as early symptom and an important cause of disability later in the disease course. Although levodopa has been shown to improve gait speed and step length, the effect of dopamine replacement therapy on other aspects of gait is less well understood. In fact, falls are not reduced and some aspects of postural instability during gait are unresponsive to dopaminergic treatment. Moreover, many medications other than dopaminergic agents, can benefit or impair gait in people with PD. We review the effects of pharmacological interventions used in PD on gait, discriminating, whenever possible, among effects on four components of everyday mobility: straight walking, gait initiation, turning, gait adaptability. Additionally, we summarize the effects on freezing of gait. There is substantial evidence for improvement of spatial characteristics of simple, straight-ahead gait with levodopa and levodopa-enhancing drugs. Recent work suggests that drugs aiming to enhance the acetylcholine system might improve gait stability measures. There is a lack of well-designed studies to evaluate effects on more complex, but highly relevant walking abilities such as turning and making flexible adjustments to gait. Finally, paucity in the literature exists on detrimental effects of drugs used in PD that are known to worsen gait and postural stability in the elderly population.

KW - Acetylcholine

KW - Dopamine

KW - Falls

KW - Gait

KW - Turning

UR - http://www.scopus.com/inward/record.url?scp=84994320305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994320305&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2016.07.006

DO - 10.1016/j.parkreldis.2016.07.006

M3 - Review article

C2 - 27461783

AN - SCOPUS:84994320305

VL - 31

SP - 3

EP - 13

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

ER -